2-氨基-5-三氟甲基苯甲酸甲酯 | 117324-58-0

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-5-三氟甲基苯甲酸甲酯
• 中文别名: 2-氨基-5-(三氟甲基)苯甲酸甲酯
• 英文名称: methyl 2-Amino-5-trifluoromethylbenzoate
• 英文别名: Methyl 2-amino-5-(trifluoromethyl)benzoate
• CAS: 117324-58-0
• 化学式: C₉H₈F₃NO₂
• mdl: MFCD08234902
• 分子量: 219.163
• InChiKey: QGFUDNJZHZNPCS-UHFFFAOYSA-N

物化性质

• 熔点：
  51-52 °C
• 沸点：
  265.9±40.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Methyl 2-amino-5-(trifluoromethyl)benzoate
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Methyl 2-amino-5-(trifluoromethyl)benzoate
Ingredient name:
CAS number: 117324-58-0

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H8F3NO2
Molecular weight: 219.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-5-三氟甲基苯甲酸甲酯 在 甲醇 、 sodium hydroxide 作用下， 反应 2.0h， 以99.36%的产率得到2-氨基-5-三氟甲基苯甲酸
  参考文献：
  名称：

  [EN] MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND THEIR USE
  [FR] MODULATEURS DU RÉCEPTEUR X2 DE LA PROTÉINE G LIÉE AU MAS ET PRODUITS APPARENTÉS ET LEUR UTILISATION

  摘要：

  本发明提供了调节MRGPRX2或MRGPRX2同源物的方法，或更具体地治疗MRGPRX2或MRGPRX2同源物依赖性疾病的方法，通过向需要的受体中注射具有结构（I）的化合物或其药学上可接受的盐、异构体、水合物、溶剂化物或同位素的有效剂量，其中W、Z、R1、R2、R3、R4、R5、R6和Rx的定义如本文所述。本发明还提供了包含这些化合物的制药组合物，以及这些化合物本身。

  公开号：

  WO2022087083A1
• 作为产物：
  描述：

  3-三氟甲基苯甲酸 在 硫酸 、 palladium 10% on activated carbon 、 氢气 、 potassium nitrate 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 39.0h， 生成 2-氨基-5-三氟甲基苯甲酸甲酯
  参考文献：
  名称：

  [EN] QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS
  [FR] DÉRIVÉS DE QUINAZOLINE-2,4(1H, 3H)-DIONE À TITRE DE MODULATEURS DE TRCP5 POUR LE TRAITEMENT DES TROUBLES NEUROPSYCHIATRIQUES

  摘要：

  该发明涉及一种新型的喹唑啉-2,4(1H,3H)-二酮衍生物，其化学式为(I)：以及它们作为TRPC5调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗TRPC5受体介导的疾病或症状的药剂的方法。R1、R2、R3和R4的含义如描述中所述。

  公开号：

  WO2016023826A1

文献信息

• [EN] NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE<br/>[FR] INHIBITEURS DE MYOSINE NON MUSCULAIRE II POUR LA RECHUTE D'UTILISATION DE SUBSTANCE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2019241469A1

  公开（公告）日：2019-12-19

  The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis/marijuana, nicotine, and activities including gambling Compounds are of general formula (I) with substituents as defined herein.

  这项发明可以提供化合物，它们是blebbistatin的类似物，相对于心肌肌球蛋白II，是有效且选择性的非肌肌球蛋白II的抑制剂。这些化合物可以用于治疗患者的疾病、紊乱或医疗状况的方法，包括调节肌球蛋白II ATP酶，如治疗物质滥用复发紊乱、肾脏疾病、癌症和转移、良性前列腺增生、止血或血栓形成、神经损伤包括视网膜损伤、肺纤维化、肝脏纤维化、关节纤维化、伤口愈合、脊髓损伤、牙周炎、青光眼和包括多发性硬化在内的免疫相关疾病；或者该疾病、紊乱或医疗状况包括成瘾，包括对《精神障碍诊断与统计手册》（DSM）中分类为物质相关或成瘾性紊乱的任何物质的滥用或成瘾，例如，但不限于，可卡因、阿片类药物、安非他明、乙醇、大麻/大麻素、尼古丁，以及包括赌博在内的活动。这些化合物具有通用的化学式（I），其取代基如本文所定义。
• [EN] COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA<br/>[FR] COMPOSES ET TECHNIQUES DE TRAITEMENT DE LA DYSLIPIDEMIE
  申请人：LILLY CO ELI

  公开号：WO2005037796A1

  公开（公告）日：2005-04-28

  Compounds of formula I wherein n, m, p, q, Y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.

  式I的化合物，其中n、m、p、q、Y、R1、R2、R3、R4、R5和R6如本文所定义，并且其药物组合物和使用方法被披露为用于治疗动脉粥样硬化及其后遗症。
• [EN] 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS<br/>[FR] COMPOSÉS 2,3-DIHYDROQUINAZOLINE EN TANT QU'INHIBITEURS DE NAV1.8
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2020261114A1

  公开（公告）日：2020-12-30

  The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X); wherein Y', X', B', R1', R2', R3', R5', R6', R7', and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.

  本发明涉及Nav1.8抑制剂2,3-二氢喹唑啉化合物，其化学公式为(X)；其中Y'、X'、B'、R1'、R2'、R3'、R5'、R6'、R7'和z1如本文所述定义；或其药用可接受的盐或互变异构体形式，相应的药物组合物或制剂，化合物制备的方法或过程，方法，化合物用于，用于治疗疼痛和/或与疼痛相关的或相关的疾病、失调或状况的使用和/或联合治疗方法。
• Cyclic derivatives as modulators of chemokine receptor activity
  申请人：Carter H. Percy

  公开号：US20050054627A1

  公开（公告）日：2005-03-10

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

  当前申请描述了MCP-1的调节剂，其化学公式为(I):或其药用可接受的盐形式，用于治疗类风湿性关节炎、多发性硬化症、动脉粥样硬化和哮喘。
• [EN] ERBB/BTK INHIBITORS<br/>[FR] INHIBITEURS DE ERBB/BTK
  申请人：DIZAL JIANGSU PHARMACEUTICAL CO LTD

  公开号：WO2019149164A1

  公开（公告）日：2019-08-08

  Disclosed are compounds inhibiting ErbBs (e. g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.

  揭示了抑制ErbBs（例如EGFR或Her 2），特别是ErbBs的突变形式，以及BTK的化合物，其药用盐、水合物、溶剂合物或立体异构体，以及包含这些化合物的药物组合物。该化合物和药物组合物可以有效治疗ErbBs（特别是ErbBs的突变形式）或与BTK相关的疾病，包括癌症。